<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01500213</url>
  </required_header>
  <id_info>
    <org_study_id>TS-P04833</org_study_id>
    <nct_id>NCT01500213</nct_id>
  </id_info>
  <brief_title>Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy</brief_title>
  <acronym>HEC</acronym>
  <official_title>A Phase 3, Multicenter, Randomized, Double Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tesaro, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tesaro, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, multicenter, randomized, parallel-group, double-blind, active-controlled
      study of rolapitant in subjects receiving HEC. Rolapitant or placebo will be administered 1-2
      hours prior to initiation of chemotherapy on Day 1 with granisetron and dexamethasone.
      Subjects will record all events of emesis and use of rescue medication for established nausea
      and/or vomiting, and will indicate the severity of nausea they experienced in each of the
      previous 24 hours in the Nausea and Vomiting (NV) Subject Diary prior to HEC administration
      through Day 6 of Cycle 1. Health-related quality of life will be measured by the FLIE
      Questionnaire on Day 6 of Cycle 1. Safety and tolerability will be assessed by clinical
      review of adverse events (AEs), physical examinations, electrocardiograms (ECGs), and safety
      laboratory values.

      All subjects are expected to complete Cycle 1 and will have the option of participating in up
      to five additional cycles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, multicenter, randomized, parallel-group, double-blind, active-controlled
      study of rolapitant in subjects receiving HEC (≥60 mg/m2 of cisplatin-based chemotherapy).
      Study drug will be administered 1 - 2 hours prior to initiation of chemotherapy on Day 1.
      Granisetron and dexamethasone will be administered approximately 30 minutes before initiation
      of chemotherapy on Day 1,except in patients receiving taxanes as part of cisplatin-based
      chemotherapy. Subjects will record all events of emesis and use of rescue medication for
      established nausea and/or vomiting and will indicate the severity of nausea they experienced
      in each of the previous 24 hours in the NV Subject Diary prior to HEC administration through
      Day 6 in Cycle 1. Dexamethasone 8 mg twice daily (part of study regimen) on Days 2 through 4
      is NOT considered rescue therapy. Health-related quality of life will be measured by the FLIE
      Questionnaire on Day 6 of Cycle 1. Safety and tolerability will be assessed by clinical
      review of AEs, physical examinations including complete neurological assessment, vital
      signs,electrocardiograms (ECGs), and safety laboratory values including BUN andcreatinine.
      All subjects are expected to complete Cycle 1 and will have the option of participating in up
      to five additional cycles. The study will investigate the efficacy of rolapitant for the
      treatment of CINV during an initial chemotherapy cycle (Cycle 1).

      Safety analyses will include data from Cycle 1 and from subsequent cycles. At the Screening
      Visit, blood samples may be collected and stored in this study and maybe analyzed for future
      biomarker research related to safety and efficacy. Analysis of these samples may include DNA,
      RNA, or protein markers. The biomarker blood samples will be stored for up to 2 years post
      study completion. In addition, PK samples will be collected from subjects enrolled in
      selected sites.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>No Emetic Episodes and No Rescue Medication</measure>
    <time_frame>&gt;24 to 120 hours post chemotherapy</time_frame>
    <description>The primary objective of this study is to determine whether administration of rolapitant with granisetron and dexamethasone improves CINV in the delayed phase (&gt;24 to 120 hours) of CINV compared with administration of placebo with granisetron and dexamethasone in subjects receiving HEC. The primary outcome will be based on complete response (defined as no emesis and no rescue medication) in the delayed phase (&gt;24 to 120 hours).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Phase Response</measure>
    <time_frame>0 to 24 hours</time_frame>
    <description>To determine the effect of rolapitant on complete response rates in the acute (0 to 24 hours) phase of CINV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>0 to 120 hours</time_frame>
    <description>To determine the effect of rolapitant on complete response rate in the overall (0 to 120 hours) phase of CINV.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">555</enrollment>
  <condition>Chemotherapy-induced Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Placebo + Granisetron + Dexamethasone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Day 1: Placebo + Granisetron (10 mcg/kg IV)+ dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rolapitant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: Rolapitant (200 mg PO) + Granisetron (10 mcg/kg IV)+ dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rolapitant</intervention_name>
    <description>200 mg PO</description>
    <arm_group_label>Rolapitant</arm_group_label>
    <other_name>Varubi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granisetron</intervention_name>
    <description>10 mcg/kg IV</description>
    <arm_group_label>Placebo + Granisetron + Dexamethasone</arm_group_label>
    <arm_group_label>Rolapitant</arm_group_label>
    <other_name>Kytril</other_name>
    <other_name>Granisol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>20 mg PO and 8 mg PO</description>
    <arm_group_label>Placebo + Granisetron + Dexamethasone</arm_group_label>
    <arm_group_label>Rolapitant</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>(4 X 0 mg capsules) o mg PO</description>
    <arm_group_label>Placebo + Granisetron + Dexamethasone</arm_group_label>
    <other_name>Placebo to match Rolapitant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older, of either gender, and of any race

          -  Has never been treated with cisplatin and is to receive the first course of
             cisplatin-based chemotherapy (≥60 mg/m2)

          -  Karnofsky performance score of ≥60

          -  Predicted life expectancy of ≥4 months

          -  Adequate bone marrow, kidney, and liver function

        Exclusion Criteria:

          -  Contraindication to cisplatin, granisetron, or dexamethasone

          -  Is pregnant or breast feeding

          -  Has previously received cisplatin or subject is planning to receive multiple days of
             cisplatin in a single cycle

          -  Has taken the following agents within the last 48 hours 5-HT3
             antagonists,Phenothiazines,Benzamides,Domperidone,Cannabinoids,NK1 antagonist,
             Benzodiazepines

          -  Scheduled to receive any other chemotherapeutic agent with an emetogenicity level of 4
             or above (Hesketh Scale) from Day 2 through Day 6, except on Day 1.

          -  Scheduled to receive any radiation therapy to the abdomen or pelvis from Day -5
             through Day 6

          -  Has received systemic corticosteroids or sedative antihistamines within 72 hours of
             Day 1 of the study except as premedication for chemotherapy (e.g., taxanes,
             pemetrexed)

          -  Symptomatic primary or metastatic CNS disease.

          -  Has ongoing vomiting, retching, clinically significant nausea caused by any etiology,
             or has a history of anticipatory nausea and vomiting.

          -  Has vomited and/or has had dry heaves/retching within 24 hours prior to the start of
             cisplatin-based chemotherapy on Day 1 in Cycle 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis Vargo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tesaro, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TESARO Inc</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2011</study_first_submitted>
  <study_first_submitted_qc>December 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2011</study_first_posted>
  <results_first_submitted>October 2, 2015</results_first_submitted>
  <results_first_submitted_qc>October 2, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 4, 2015</results_first_posted>
  <last_update_submitted>February 2, 2016</last_update_submitted>
  <last_update_submitted_qc>February 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rolapitant</keyword>
  <keyword>Nausea</keyword>
  <keyword>Vomiting</keyword>
  <keyword>CINV</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Granisetron</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>8-((1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,7-diazaspiro(4,5)decan-2-one</mesh_term>
    <mesh_term>Emetics</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rolapitant + Granisetron + Dexamethasone</title>
          <description>Oral dose of rolapitant 180 mg (equivalent to 200 mg rolapitant hydrochloride monohydrate) 1–2 h before administration of chemotherapy
Granisetron (10 μg/kg intravenously) about 30 min before chemotherapy
Dexamethasone (20 mg orally) about 30 min before chemotherapy, and dexamethasone 8 mg orally twice daily on days 2–4</description>
        </group>
        <group group_id="P2">
          <title>Placebo + Granisetron + Dexamethasone</title>
          <description>Matching placebo 1–2 h before administration of chemotherapy
Granisetron (10 μg/kg intravenously) about 30 min before chemotherapy
Dexamethasone (20 mg orally) about 30 min before chemotherapy, and dexamethasone 8 mg orally twice daily on days 2–4</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="278">Number of randomized patients</participants>
                <participants group_id="P2" count="277"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61">Number of patients who completed 6 cycles</participants>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="217"/>
                <participants group_id="P2" count="224"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Chemo Completed or Change in Therapy</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="81"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reasons</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>MITT population: 278 subjects were randomized to Rolapitant and 277 were randomized to control, 272 of those randomized to Rolapitant received study drug in C1; 274 of those who were randomized to control received study drug in C1, 1 Rolapitant subject and 1 control subject were from GCP-non-compliant sites.</population>
      <group_list>
        <group group_id="B1">
          <title>Rolapitant + Granisetron + Dexamethasone</title>
          <description>Oral dose of rolapitant 180 mg (equivalent to 200 mg rolapitant hydrochloride monohydrate) 1–2 h before administration of chemotherapy
Granisetron (10 μg/kg intravenously) about 30 min before chemotherapy
Dexamethasone (20 mg orally) about 30 min before chemotherapy, and dexamethasone 8 mg orally twice daily on days 2–4</description>
        </group>
        <group group_id="B2">
          <title>Placebo + Granisetron + Dexamethasone</title>
          <description>Matching placebo 1–2 h before administration of chemotherapy
Granisetron (10 μg/kg intravenously) about 30 min before chemotherapy
Dexamethasone (20 mg orally) about 30 min before chemotherapy, and dexamethasone 8 mg orally twice daily on days 2–4</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="271"/>
            <count group_id="B2" value="273"/>
            <count group_id="B3" value="544"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.5" spread="10.05"/>
                    <measurement group_id="B2" value="58.5" spread="9.25"/>
                    <measurement group_id="B3" value="58.5" spread="9.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="235"/>
                    <measurement group_id="B2" value="235"/>
                    <measurement group_id="B3" value="470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="226"/>
                    <measurement group_id="B2" value="212"/>
                    <measurement group_id="B3" value="438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>No Emetic Episodes and No Rescue Medication</title>
        <description>The primary objective of this study is to determine whether administration of rolapitant with granisetron and dexamethasone improves CINV in the delayed phase (&gt;24 to 120 hours) of CINV compared with administration of placebo with granisetron and dexamethasone in subjects receiving HEC. The primary outcome will be based on complete response (defined as no emesis and no rescue medication) in the delayed phase (&gt;24 to 120 hours).</description>
        <time_frame>&gt;24 to 120 hours post chemotherapy</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>Rolapitant + Granisetron + Dexamethasone</title>
            <description>Oral dose of rolapitant 180 mg (equivalent to 200 mg rolapitant hydrochloride monohydrate) 1–2 h before administration of chemotherapy
Granisetron (10 μg/kg intravenously) about 30 min before chemotherapy
Dexamethasone (20 mg orally) about 30 min before chemotherapy, and dexamethasone 8 mg orally twice daily on days 2–4</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Granisetron + Dexamethasone</title>
            <description>Matching placebo 1–2 h before administration of chemotherapy
Granisetron (10 μg/kg intravenously) about 30 min before chemotherapy
Dexamethasone (20 mg orally) about 30 min before chemotherapy, and dexamethasone 8 mg orally twice daily on days 2–4</description>
          </group>
        </group_list>
        <measure>
          <title>No Emetic Episodes and No Rescue Medication</title>
          <description>The primary objective of this study is to determine whether administration of rolapitant with granisetron and dexamethasone improves CINV in the delayed phase (&gt;24 to 120 hours) of CINV compared with administration of placebo with granisetron and dexamethasone in subjects receiving HEC. The primary outcome will be based on complete response (defined as no emesis and no rescue medication) in the delayed phase (&gt;24 to 120 hours).</description>
          <population>MITT</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.1" lower_limit="64.3" upper_limit="75.5"/>
                    <measurement group_id="O2" value="61.9" lower_limit="55.9" upper_limit="67.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.043</p_value>
            <p_value_desc>To control for multiplicity, analyses were performed hierarchically. For the CR delayed the threshold for statistical significance was 0.05; no further adjustment for multiplicity were required for the primary endpoint.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran Mantel Haenszel (CMH) test was stratified by sex. Missing data were imputed as treatment failures.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Phase Response</title>
        <description>To determine the effect of rolapitant on complete response rates in the acute (0 to 24 hours) phase of CINV.</description>
        <time_frame>0 to 24 hours</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>Rolapitant + Granisetron + Dexamethasone</title>
            <description>Oral dose of rolapitant 180 mg (equivalent to 200 mg rolapitant hydrochloride monohydrate) 1–2 h before administration of chemotherapy
Granisetron (10 μg/kg intravenously) about 30 min before chemotherapy
Dexamethasone (20 mg orally) about 30 min before chemotherapy, and dexamethasone 8 mg orally twice daily on days 2–4</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Granisetron + Dexamethasone</title>
            <description>Matching placebo 1–2 h before administration of chemotherapy
Granisetron (10 μg/kg intravenously) about 30 min before chemotherapy
Dexamethasone (20 mg orally) about 30 min before chemotherapy, and dexamethasone 8 mg orally twice daily on days 2–4</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Phase Response</title>
          <description>To determine the effect of rolapitant on complete response rates in the acute (0 to 24 hours) phase of CINV.</description>
          <population>MITT</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.4" lower_limit="78.4" upper_limit="87.6"/>
                    <measurement group_id="O2" value="79.5" lower_limit="74.2" upper_limit="84.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.233</p_value>
            <p_value_desc>To control for multiplicity, analyses were performed hierarchically. CR-acute was tested only if the result for the primary endpoint, CR delayed, was statistically significant.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran Mantel Haenszel (CMH) test was stratified by sex. Missing data were imputed as treatment failures.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate</title>
        <description>To determine the effect of rolapitant on complete response rate in the overall (0 to 120 hours) phase of CINV.</description>
        <time_frame>0 to 120 hours</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>Rolapitant + Granisetron + Dexamethasone</title>
            <description>Oral dose of rolapitant 180 mg (equivalent to 200 mg rolapitant hydrochloride monohydrate) 1–2 h before administration of chemotherapy
Granisetron (10 μg/kg intravenously) about 30 min before chemotherapy
Dexamethasone (20 mg orally) about 30 min before chemotherapy, and dexamethasone 8 mg orally twice daily on days 2–4</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Granisetron + Dexamethasone</title>
            <description>Matching placebo 1–2 h before administration of chemotherapy
Granisetron (10 μg/kg intravenously) about 30 min before chemotherapy
Dexamethasone (20 mg orally) about 30 min before chemotherapy, and dexamethasone 8 mg orally twice daily on days 2–4</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>To determine the effect of rolapitant on complete response rate in the overall (0 to 120 hours) phase of CINV.</description>
          <population>MITT</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.5" lower_limit="61.6" upper_limit="73.1"/>
                    <measurement group_id="O2" value="60.4" lower_limit="54.4" upper_limit="66.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.084</p_value>
            <p_value_desc>To control for multiplicity, analyses were performed hierarchically. CR overall was tested only if both CR delayed and CR acute were statistically significant.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran Mantel Haenszel (CMH) test was stratified by sex. Missing data were imputed as treatment failures.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 6 cycles (median number of cycles=3; median duration of each cycle = 21-23 days) of treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rolapitant + Granisetron + Dexamethasone</title>
          <description>Oral dose of rolapitant 180 mg (equivalent to 200 mg rolapitant hydrochloride monohydrate) 1–2 h before administration of chemotherapy
Granisetron (10 μg/kg intravenously) about 30 min before chemotherapy
Dexamethasone (20 mg orally) about 30 min before chemotherapy, and dexamethasone 8 mg orally twice daily on days 2–4
278 subjects were randomized to Rolapitant
272 of those randomized to Rolapitant received Rolapitant in C1
Safety = 272 Rolapitant</description>
        </group>
        <group group_id="E2">
          <title>Placebo + Granisetron + Dexamethasone</title>
          <description>Matching placebo 1–2 h before administration of chemotherapy
Granisetron (10 μg/kg intravenously) about 30 min before chemotherapy
Dexamethasone (20 mg orally) about 30 min before chemotherapy, and dexamethasone 8 mg orally twice daily on days 2–4
277 subjects were randomized to control;
274 of those who were randomized to control received control in C1.
Safety = 274 control</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Aphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Gastric Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Ileus Paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Disease Progression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>General Physical Health Deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Spinal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary Colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Device Related Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Encephalitis Herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Klebsiella Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Neutropenic Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pseudomonal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Toxicity to Various Agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Leukoerythroblastosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Oral Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Tumour Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Hepatic Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Axillary Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Circulatory Collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Iliac Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Peripheral Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Subclavian Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="225" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="211" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Mucosal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Martin Huber, M.D., Senior Vice President and Chief Medical Officer</name_or_title>
      <organization>Tesaro</organization>
      <phone>862.228.2483</phone>
      <email>mhuber@tesarobio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

